Identification of a PCSK9-LDLR disruptor peptide with in vivo function-Reference-Cited by-同舟云学术

Identification of a PCSK9-LDLR disruptor peptide with in vivo function

Published:2021-09 Issue: Volume: Page:
ISSN:2451-9456
Container-title:Cell Chemical Biology
language:en
Short-container-title:Cell Chemical Biology

Author:

Brousseau Margaret E.,Clairmont Kevin B.^ORCID,Spraggon Glen,Flyer Alec N.,Golosov Andrei A.,Grosche Philipp,Amin Jakal,Andre Jerome,Burdick Debra,Caplan Shari,Chen Guanjing,Chopra Raj,Ames Lisa,Dubiel Diana,Fan Li,Gattlen Raphael,Kelly-Sullivan Dawn,Koch Alexander W.,Lewis Ian,Li Jingzhou,Liu Eugene,Lubicka Danuta,Marzinzik Andreas,Nakajima Katsumasa,Nettleton David^ORCID,Ottl Johannes,Pan Meihui,Patel Tajesh,Perry Lauren,Pickett Stephanie,Poirier Jennifer,Reid Patrick C.,Pelle Xavier,Seepersaud Mohindra,Subramanian Vanitha,Vera Victoria,Xu Mei,Yang Lihua,Yang Qing,Yu Jinghua,Zhu Guoming,Monovich Lauren G.

Funder

Novartis Institutes for BioMedical Research

Novartis

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,Biochemistry

Reference49 articles.

1. Anti-proprotein Convertase Subtilisin Kexin Type 9 (Anti-pcsk9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases;Abdel-Meguid,2017

2. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia;Abifadel;Nat. Genet.,2003

3. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation;Alghamdi;Eur. J. Med. Chem.,2015

4. Series of novel and highly potent cyclic peptide PCSK9 inhibitors derived from an mRNA display screen and optimized via structure-based design;Alleyne;J. Med. Chem.,2020

5. A receptor-mediated pathway for cholesterol homeostasis;Brown;Science,1986

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Berberine: A Multi-Target Natural PCSK9 Inhibitor with the Potential to Treat Diabetes, Alzheimer’s, Cancer and Cardiovascular Disease;Current Reviews in Clinical and Experimental Pharmacology;2024-11

2. LW-213, a derivative of wogonin, triggers reticulophagy-mediated cell death in NSCLC via lysosomal damage combined with NPC1 inhibition;Phytomedicine;2024-11

3. E3 ubiquitin ligase MARCH1 reduces inflammation and pyroptosis in cerebral ischemia-reperfusion injury via PCSK9 downregulation;Mammalian Genome;2024-08-08

4. Chenodeoxycholic Acid‐Modified Polyethyleneimine Nano‐Composites Deliver Low‐Density Lipoprotein Receptor Genes for Lipid‐Lowering Therapy by Targeting the Liver;Advanced Healthcare Materials;2024-06-16

5. A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis;Acta Pharmacologica Sinica;2024-05-29